Almirall has licensed an interleukin-2 (IL-2) drug from China's Simcere Pharma, joining the ranks of companies looking at blocking the cytokine as a way to treat autoimmune diseases.

Almirall has signed a new research collaboration with Chinese biotech HitGen, to find potential new oral therapies for moderate to severe atopic dermatitis – otherwise known as eczema.

BARCELONA, Spain--(BUSINESS WIRE)--Almirall, S.A. (ALM): Financial highlights (€ rounded million) "2024 was an important year for Almirall as European leader in Medical Dermatology: we delivered ...

"2024 was an important year for Almirall as European leader in Medical Dermatology: we delivered impactful products to more patients and the medical community. Our double-digit sales growth and ...

(Reuters) - Spanish pharmaceutical company Almirall expects to almost double its annual revenue by 2030, boosted by higher sales of its dermatological products in Europe, CEO Carlos Gallardo said ...

Almirall´s strong presence at the AAD conference, sharing new data on Almirall’s dermatology and pipeline portfolio demonstrate its dedication to the medical community and patients living with ...

Jefferies analyst Lucy Codrington maintained a Buy rating on Almirall (0O9B – Research Report) yesterday and set a price target of €17.00. The company’s shares closed yesterday at €9.86.